Group 1 - The Hong Kong innovative drug ETF (159567) experienced volatility, with a decline of 1.29% as of the report, after a previous increase of 5.23% [1] - The ETF closely tracks the Hong Kong Stock Connect Innovative Drug Index (987018), reflecting the performance characteristics of listed biotech companies in Hong Kong [1] - Major component stocks such as WuXi Biologics and WuXi AppTec saw gains, indicating positive market sentiment towards the innovative drug sector [1] Group 2 - The systematic valuation increase in the innovative drug sector is seen as a major catalyst for industry allocation, driven by the recognition of Chinese innovative drug companies' business models [2] - Leading companies are entering profitability, and their R&D pipelines are beginning to generate consistent revenue, leading to a systematic valuation uplift [2] - The international competitiveness of Chinese innovative drug products is improving, as evidenced by their contributions at the 2025 ASCO annual meeting [2]
昨日收涨5.23%，港股创新药ETF（159567）成交额快速超10亿元，机构：创新药受到基本面与交易面多重催化
2 1 Shi Ji Jing Ji Bao Dao·2025-06-13 02:14